Kevin M Kalinsky (Kevin Kalinsky)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 35

Top Topics

Epidermal Growth Factor Receptor

Top Venues

NPJ breast cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo, Marie Davidian, Butch Tsiatis, Anne M Wallace, A Jo Chien, Erica Stringer-Reasor, Judy C Boughey, Coral Omene, Mariya Rozenblit, Kevin M Kalinsky, Anthony D Elias, Christos Vaklavas, Heather Beckwith, Nicole Williams, Mili Arora, Chaitali Nangia, Evanthia T Roussos Torres, Brittani Thomas, Kathy S Albain, Amy S Clark, Carla Falkson, Dawn L Hershman, Claudine Isaacs, Alexandra Thomas, Jennifer Tseng, Amy Sanford, Kay Yeung, Sarah Boles, Yunni Yi Chen, Laura Huppert, Nusrat Jahan, Catherine Parker, Karthik Giridhar, Frederick M Howard, M Michele Blackwood, Tara Sanft, Wen Li, Natsuko Onishi, Adam L Asare, Philip Beineke, Peter Norwood, Lamorna Brown Swigart, Gillian L Hirst, Jeffrey B Matthews, Brian Moore, William Fraser Symmans, Elissa Price, Diane Heditsian, Barbara LeStage, Jane Perlmutter, Paula R Pohlmann, Angela M DeMichele, Douglas Yee, Laura van 't Veer, Nola M Hylton, Laura J Esserman
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine (2024)
Aditya Bardia, Komal L Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, Shu-Sen Wang, Noelia Martínez Jañez, Giuliano Borges, David W Cescon, Masaya Hattori, Yen-Shen Lu, Erika Paige Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin M Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M Fairhurst, Sabrina Khan, Neelima Denduluri, Hope S Rugo, Binghe Xu, Barbara Pistilli, null null
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Claire Sathe, Rohit Raghunathan, Sophie R Ulene, Fiona McAuley, Kishan A Bhatt, Julia E McGuinness, Meghna S Trivedi, Neil Vasan, Kevin M Kalinsky, Katherine D Crew, Khadija F Faheem, Erik Harden, Cynthia Law, Dawn L Hershman, Melissa K Accordino
Use of a Smartphone Application to Promote Adherence to Oral Medications in Patients With Breast Cancer. JCO oncology practice (2024)
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda, Marie Davidian, Butch Tsiatis, A Jo Chien, Anne M Wallace, Mili Arora, Mariya Rozenblit, Dawn L Hershman, Alexandra S Zimmer, Amy S Clark, Heather Beckwith, Anthony D Elias, Erica Stringer-Reasor, Judy C Boughey, Chaitali Nangia, Christos Vaklavas, Coral Omene, Kathy S Albain, Kevin M Kalinsky, Claudine Isaacs, Jennifer Tseng, Evanthia T Roussos Torres, Brittani Thomas, Alexandra Thomas, Amy Sanford, Ronald Balassanian, Cheryl Ewing, Kay Yeung, Candice A M Sauder, Tara Sanft, Lajos Pusztai, Meghna S Trivedi, Ashton Outhaythip, Wen Li, Natsuko Onishi, Adam L Asare, Philip Beineke, Peter Norwood, Lamorna Brown Swigart, Gillian L Hirst, Jeffrey B Matthews, Brian Moore, W Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula R Pohlmann, Rebecca A Shatsky, Angela M DeMichele, Douglas Yee, Laura van 't Veer, Nola M Hylton, Laura J Esserman
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Komal L Jhaveri, Melissa K Accordino, Philippe L Bedard, Andres Cervantes, Valentina Gambardella, Erika Paige Hamilton, Antoine Italiano, Kevin M Kalinsky, Ian E Krop, Mafalda Oliveira, Peter Schmid, Cristina Saura, Nicholas C Turner, Andrea Varga, Sravanthi Cheeti, Stephanie Hilz, Katherine E Hutchinson, Yanling Jin, Stephanie Royer-Joo, Ubong Peters, Noopur Shankar, Jennifer L Schutzman, Dejan Juric
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Aditya Bardia, Hope S Rugo, Sara M Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam M Brufsky, Kevin M Kalinsky, Javier Cortes, Joyce O' Shaughnessy, Véronique Diéras, Lisa Anne Carey, Luca Gianni, Martine J Piccart, Sibylle Loibl, Oh Kyu Yoon, Yang Pan, Scott Hofsess, See-Chun Phan, Sara Alsterlind Hurvitz
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (15) (2024)
Sara Alsterlind Hurvitz, Aditya Bardia, Kevin Punie, Kevin M Kalinsky, Lisa Anne Carey, Hope S Rugo, Véronique Diéras, See Phan, Rosemary Delaney, Yanni Zhu, Sara M Tolaney
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ breast cancer 10 (1) (2024)
Anne Loeser, Janice S Kim, Jeffrey M Peppercorn, Mark E Burkard, Andrzej Niemierko, Dejan Juric, Kevin M Kalinsky, Hope S Rugo, Lesley Glenn, Christine Hodgdon, Julia Maués, Sheila Johnson, Natalia Padron, Kimberly Parekh, Maryam B Lustberg, Aditya Bardia
The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO oncology practice (2024)
Claire Sathe, Rohit Raghunathan, Sophie R Ulene, Fiona McAuley, Kishan A Bhatt, Julia E McGuinness, Meghna S Trivedi, Neil Vasan, Kevin M Kalinsky, Katherine D Crew, Khadija F Faheem, Erik Harden, Cynthia Law, Dawn L Hershman, Melissa K Accordino
Use of a Smartphone Application to Promote Adherence to Oral Medications in Patients With Breast Cancer. JCO oncology practice (2024)
Anne Loeser, Janice S Kim, Jeffrey M Peppercorn, Mark E Burkard, Andrzej Niemierko, Dejan Juric, Kevin M Kalinsky, Hope S Rugo, Lesley Glenn, Christine Hodgdon, Julia Maués, Sheila Johnson, Natalia Padron, Kimberly Parekh, Maryam B Lustberg, Aditya Bardia
The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO oncology practice 20 (7) (2024)
Prabhjot S Mundi, Filemon Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R Rainey, Kristina Guillan, Armaan Siddiquee, Daoqi You, Ronald Realubit, Charles Karan, Michael V Ortiz, Eugene F Douglass, Melissa K Accordino, Suzanne Mistretta, Frances L Brogan, Jeffrey N Bruce, Cristina I Caescu, Richard D Carvajal, Katherine D Crew, Guarionex Decastro, Mark Heaney, Brian S Henick, Dawn L Hershman, June Y Hou, Fabio M Iwamoto, Joseph G Jurcic, Ravi P Kiran, Michael D Kluger, Teri Kreisl, Nicole Lamanna, Andrew B Lassman, Emerson A Lim, Gulam A Manji, Guy M McKhann, James M McKiernan, Alfred I Neugut, Kenneth P Olive, Todd Rosenblat, Gary K Schwartz, Catherine A Shu, Michael B Sisti, Ana I Tergas, Reena M Vattakalam, Mary R Welch, Sven Wenske, Jason D Wright, Peter Canoll, Hanina Hibshoosh, Kevin M Kalinsky, Mahalaxmi Aburi, Peter A Sims, Mariano J Alvarez, Andrew L Kung, Andrea Califano
A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies. Cancer discovery (2023)
Kevin M Kalinsky, Melissa K Accordino, Codruta Chiuzan, Prabhjot S Mundi, Elizabeth Sakach, Claire Sathe, Heejoon Ahn, Meghna S Trivedi, Yelena Novik, Amy Tiersten, George Raptis, Lea N Baer, Sun Y Oh, Amelia B Zelnak, Kari B Wisinski, Eleni Andreopoulou, William J Gradishar, Erica M Stringer-Reasor, Sonya A Reid, Anne O'Dea, Ruth M O'Regan, Katherine D Crew, Dawn L Hershman
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S L Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R Lloyd, Avinash Kambadakone, Laura M Spring, Douglas S Micalizzi, Maristela L Onozato, Dante Che, Utthara Nayar, Adam M Brufsky, Kevin M Kalinsky, Cynthia X Ma, Joyce O'Shaughnessy, Hyo S Han, Anthony J Iafrate, Lianne Y Ryan, Dejan Juric, Beverly Moy, Leif W Ellisen, Shyamala Maheswaran, Nikhil Wagle, Daniel A Haber, Aditya Bardia, Seth A Wander
A Gene Panel Associated With Abemaciclib Utility in ESR1 -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO precision oncology 7 (2023)
Jamie O Brett, Taronish D Dubash, Gabriela N Johnson, Andrzej Niemierko, Veronica Mariotti, Leslie S L Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Maxwell R Lloyd, Avinash Kambadakone, Laura M Spring, Douglas S Micalizzi, Maristela L Onozato, Dante Che, Utthara Nayar, Adam M Brufsky, Kevin M Kalinsky, Cynthia X Ma, Joyce O'Shaughnessy, Hyo S Han, Anthony J Iafrate, Lianne Y Ryan, Dejan Juric, Beverly Moy, Leif W Ellisen, Shyamala Maheswaran, Nikhil Wagle, Daniel A Haber, Aditya Bardia, Seth A Wander
A Gene Panel Associated With Abemaciclib Utility in ESR1 -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. JCO precision oncology 7 (2023)
Jose Silva, Jiyang Yu, Kevin M Kalinsky
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor. Nature cancer (2023)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer (2022)
Tao Qing, Thomas Karn, Mariya Rozenblit, Julia Foldi, Michał Marczyk, Naing Lin Shan, Kim R M Blenman, Uwe Holtrich, Kevin M Kalinsky, Funda Meric-Bernstam, Lajos Pusztai
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. NPJ breast cancer 8 (1) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)